Table 4.
Association between prescribing and industry payments adjusted for gender, practice group size, years since graduation and region
| Drug name1 | Probability of prescribing without payments, % | Increase in probability of prescribing per $1000 in consulting / compensation payments, %2 | Odds ratio per $1000 consulting / compensation payments (95%CI)2 | Increase in probability of prescribing per $100 in food / beverage payments, %2 | Odds ratio per $100 food / beverage payments (95%CI)2 |
|---|---|---|---|---|---|
| rACTH | 1.8 | 0.4 | 1.24 (1.18, 1.31) | 1.4 | 2.10 (1.84, 2.41) |
| Adalimumab | 78.3 | 5.9 | 1.48 (1.27, 1.72) | 11.0 | 1.97 (1.75, 2.22) |
| Etanercept | 83.4 | 1.3 | 1.10 (0.97, 1.25) | 11.3 | 2.57 (2.10, 3.14) |
| Infliximab | 20.8 | 21.5 | 2.80 (2.01, 3.89) | 37.1 | 5.69 (4.40, 7.36) |
| Golimumab | 20.4 | 1.5 | 1.09 (1.05, 1.14) | 6.7 | 1.50 (1.39, 1.62) |
| Rituximab | 6.3 | 1.3 | 1.23 (1.11, 1.36) | 6.7 | 2.69 (2.33, 3.10) |
| Certolizumab | 19.1 | 2.9 | 1.20 (1.11, 1.29) | 4.9 | 1.36 (1.25, 1.47) |
| Abatacept | 38.3 | 1.2 | 1.05 (1.01, 1.10) | 13.7 | 1.77 (1.58, 1.98) |
| Teriparatide | 31.1 | 59.3 | 20.9 (3.58, 121.9) | 74.5 | 382.9 (196.0,747.9) |
| Denosumab | 30.7 | 5.0 | 1.26 (1.02, 1.55) | 34.9 | 4.54 (3.81, 5.40) |
1
There were no payments associated with hydroxychloroquine. Methotrexate and prednisone were excluded since more than 96% of the prescriptions were generic with no payment association.
2
Consulting and compensation=Speaker fees, consulting fees, honorariums, travel costs and grants; type2=food and beverages, gifts, education, entertainment
rACTH, Repository corticotropin